Allosteric Binding Agents Stabilize Transient Protein Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for stabilizing transient protein complexes, making them difficult to investigate structurally and target for drug discovery due to their transient nature and lack of selective stabilization tools.
Innovation Solution
A method for generating and selecting allosteric binding agents that selectively stabilize transient protein complexes by binding to unique conformational epitopes, using thermodynamic cycles to quantify the stability contribution of these agents and employing cell sorting to identify and isolate binding agents that specifically bind to protein complexes rather than their individual members.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional purification and structural biology methods are used on transient protein complexes, then the complexes can be studied structurally, but the transient nature of the complexes causes them to dissociate during the process, preventing successful structural determination
Solution Approach 1:
The patent uses binding agents (such as antibodies or antibody fragments) as intermediary molecules that selectively bind to transient protein complexes to stabilize them. These binding agents act as mediators between the transient complex and the structural biology methods, preventing dissociation during purification and crystallization processes while enabling successful structural determination
Solution Approach 2:
The patent employs binding agents that alter the thermodynamic parameters of the protein complex system. By introducing binding agents with specific affinity constants, the equilibrium is shifted toward the complexed form, changing the stability parameters and enabling structural studies that would otherwise be impossible with transient complexes
2Reliability
If binding agents are used to stabilize transient protein complexes, then structural investigation becomes feasible, but the binding agents must selectively bind to the complex rather than individual proteins to maintain physiological relevance
Solution Approach 1:
The patent employs preliminary action by pre-stabilizing transient protein complexes through chemical cross-linking or other stabilization methods before exposing them to the binding agent library. This preliminary stabilization ensures that the complexes maintain their native conformation and interaction interfaces during the binding agent selection process, enabling identification of agents that recognize genuine complex epitopes
Solution Approach 2:
The patent segments the selection process into distinct sequential steps: first selecting binding agents that bind to the stabilized complex, then filtering out agents that bind to individual proteins. This segmentation of the selection workflow into discrete stages enables systematic identification of truly complex-selective binding agents while managing the overall complexity of the process
3Measurement precision
If high-resolution 3D structures are obtained for protein complexes, then key atomic details about binding interfaces and structural changes are revealed, but the transient and dynamic nature of many PPIs makes them difficult targets for structural characterization
Solution Approach 1:
The patent uses binding agents as intermediary molecules that stabilize transient protein complexes, enabling the accumulation of sufficient stable complex material for structural biology methods. These mediators allow high-resolution structural determination by preventing dissociation during the prolonged purification and crystallization processes required for techniques like X-ray crystallography and NMR
Solution Approach 2:
The patent applies preliminary stabilization of transient complexes using binding agents before structural biology experiments. This preliminary action ensures that sufficient quantities of stable, well-defined complex material are available for high-resolution structural characterization, overcoming the limitation of transient complex dissociation during the extensive material preparation required for techniques requiring milligram quantities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the stabilization and structural investigation of transient protein complexes, facilitating drug discovery and disease treatment by providing tools that selectively bind to specific conformations of protein complexes, thereby enhancing our understanding and manipulation of protein interactions.
Implementation Method 1
binding agents that selectively stabilize transient protein complexes by binding to unique conformational epitopes
Implementation Method 2
employing cell sorting to identify and isolate binding agents that specifically bind to protein complexes rather than their individual members
Implementation Method 3
using thermodynamic cycles to quantify the stability contribution of these agents
Data Source
AI summary
The application relates to the field of structural biology. More specifically, the disclosure relates to methods for the identification and characterization of biomolecular tools allowing the selective recognition and/or stabilization of distinct conformational states of protein complexes, including transient protein-protein interactions and protein-nucleic acid complexes. Such tools can then be used for purification purposes, crystallization and structure determination of these stabilized protein complexes, for drug discovery, as research tools, as well as for diagnosis and treatment of diseases.